Allspring Global Investments Holdings LLC Has $50.07 Million Position in Haemonetics Corporation $HAE

Allspring Global Investments Holdings LLC decreased its holdings in shares of Haemonetics Corporation (NYSE:HAE) by 5.3% in the 1st quarter, Holdings Channel.com reports. The firm owned 890,224 shares of the medical instruments supplier’s stock after selling 49,503 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Haemonetics were worth $50,066,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Principal Financial Group Inc. grew its stake in shares of Haemonetics by 25.4% in the first quarter. Principal Financial Group Inc. now owns 205,456 shares of the medical instruments supplier’s stock worth $11,580,000 after acquiring an additional 41,677 shares during the last quarter. Hsbc Holdings PLC raised its stake in Haemonetics by 239.6% during the 1st quarter. Hsbc Holdings PLC now owns 37,256 shares of the medical instruments supplier’s stock valued at $2,097,000 after purchasing an additional 26,284 shares during the last quarter. Y Intercept Hong Kong Ltd raised its stake in Haemonetics by 125.7% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 51,334 shares of the medical instruments supplier’s stock valued at $2,893,000 after purchasing an additional 28,586 shares during the last quarter. Peregrine Capital Management LLC raised its stake in Haemonetics by 47.4% during the 1st quarter. Peregrine Capital Management LLC now owns 42,163 shares of the medical instruments supplier’s stock valued at $2,376,000 after purchasing an additional 13,553 shares during the last quarter. Finally, Inspire Investing LLC grew its position in Haemonetics by 56.2% in the 1st quarter. Inspire Investing LLC now owns 9,099 shares of the medical instruments supplier’s stock worth $513,000 after purchasing an additional 3,272 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. decreased their target price on Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a research report on Friday, May 8th. Citigroup reaffirmed a “neutral” rating on shares of Haemonetics in a report on Wednesday, July 8th. Barrington Research reduced their price objective on Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a research report on Tuesday, May 12th. Mizuho lifted their price objective on Haemonetics from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Weiss Ratings upgraded Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.89.

Haemonetics Price Performance

Shares of Haemonetics stock opened at $77.97 on Friday. The company has a debt-to-equity ratio of 1.53, a quick ratio of 1.87 and a current ratio of 2.95. The firm’s 50-day simple moving average is $70.49 and its 200-day simple moving average is $66.25. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32. The firm has a market cap of $3.54 billion, a P/E ratio of 38.60, a price-to-earnings-growth ratio of 1.57 and a beta of 0.52.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The company had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. During the same period in the prior year, the company posted $1.24 EPS. The company’s revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, research analysts expect that Haemonetics Corporation will post 5.21 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.